Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

News SummaryMost relevantAll newsSector newsTweets

Merck & Co., Inc. : Merck On Track to File Application for Insomnia Drug This Year

share with twitter share with LinkedIn share with facebook
share via e-mail
06/13/2012 | 02:52pm CEST
   By Victoria Stilwell 

Merck & Co. (MRK) said it is on track to file a new drug application for its experimental insomnia medicine this year, making the drug one of six major filings planned for 2012 and 2013.

Data from a Phase 3 clinical trial showed Merck's insomnia drug suvorexant reduced the time it took patients to fall asleep and increased the time patients stayed asleep as early as the first night and at the three-month point compared with a placebo.

The drug met statistical significance on 15 out of 16 primary endpoints. The findings were to be presented at the Annual Meeting of the Associated Professional Sleep Societies.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

Merck reported in April first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed at $38.43 Tuesday and were inactive in premarket trade. The stock is up 8.8% in the past 12 months.

Write to Victoria Stilwell at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
09/19 MERCK AND : Pro Baseball Hall of Famer and Cancer Survivor Mike Schmidt Joins Me..
09/14 MERCK AND : Rigontec Acquired by MSD
09/14 MERCK AND COMPANY : ex-dividend day
09/12 NOW AVAILABLE IN CANADA : ISENTRESS® HD (raltegravir), a New Once-Daily Option, ..
09/12 MERCK AND : KEYTRUDA Plus Pemetrexed and Carboplatin Demonstrated Continued Bene..
09/12 MERCK AND : KEYTRUDA Continues to Show Overall Survival Benefit over Chemotherap..
09/12 MERCK AND : Updated Data for Merck's KEYTRUDA in Patients with Advanced Gastric ..
09/12 MERCK AND : Incyte chalk up promising melanoma data for Keytruda-epacadostat com..
09/11 EISAI : Signs agreement with merck & co., inc., kenilworth, nj, usa to expand en..
09/11 MERCK AND : to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadershi..
More news
News from SeekingAlpha
09/18 NOVARTIS : The Value Creator
09/17 GALILEO'S LAMENT : The Rejection Of Science Hurts The Economy
09/16 Stocks to watch next week
09/16 3 THINGS IN BIOTECH YOU SHOULD LEARN : September 16, 2017
09/14 Achillion Is Crushed As Johnson & Johnson Heads For The Exit
Financials ($)
Sales 2017 40 322 M
EBIT 2017 13 720 M
Net income 2017 5 622 M
Debt 2017 5 470 M
Yield 2017 2,85%
P/E ratio 2017 32,97
P/E ratio 2018 19,69
EV / Sales 2017 4,60x
EV / Sales 2018 4,49x
Capitalization 180 B
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 70,0 $
Spread / Average Target 6,1%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY12.38%179 978
JOHNSON & JOHNSON16.70%363 360
NOVARTIS11.20%223 865
ROCHE HOLDING LTD.4.56%219 130
PFIZER9.45%211 705
SANOFI5.81%123 374